Guardian Angel (G-Angel) spun out from the University of Akron, OH in 2019. It started with the vision to save sudden cardiac arrest victims by injecting IV medication such as epinephrine. Through market research, we learned over 1 billion IV accesses performed worldwide are only accessible through limited healthcare providers which significantly limits the treatment options for patients and increases the cost of treatment. G-Angel is on the mission to automate IV access to empower patients to be independent in their IV therapies and reduces the cost of treatment. PIV will be the first technology that hides the needle in an IV access procedure to alleviate the fear of the needle affecting almost 50 million Americans.